These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 21152689)

  • 1. [Tracers in oncology - preclinical and clinical evaluation].
    Krause BJ; Schwarzenböck S; Schwaiger M
    Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT and choline: diagnosis and staging.
    Farsad M; Schwarzenböck S; Krause BJ
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-FDG PET in the practice of oncology.
    Caroli P; Nanni C; Rubello D; Alavi A; Fanti S
    Indian J Cancer; 2010; 47(2):120-5. PubMed ID: 20448372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of new PET tracers for lung cancer.
    Szyszko TA; Yip C; Szlosarek P; Goh V; Cook GJ
    Lung Cancer; 2016 Apr; 94():7-14. PubMed ID: 26973200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET and PET/CT studies of tumor tissue oxygenation.
    Krause BJ; Beck R; Souvatzoglou M; Piert M
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):28-43. PubMed ID: 16557202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non FDG PET.
    Nanni C; Fantini L; Nicolini S; Fanti S
    Clin Radiol; 2010 Jul; 65(7):536-48. PubMed ID: 20541653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT in prostate cancer: non-choline radiopharmaceuticals.
    Castellucci P; Jadvar H
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):367-74. PubMed ID: 23013666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging (PET) of brain tumors.
    Basu S; Alavi A
    Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET tracers in musculoskeletal disease beyond FDG.
    Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
    Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumor markers and PET/CT imaging for tumor recurrence detection.
    Kruse V; Cocquyt V; Borms M; Maes A; Van de Wiele C
    Ann Nucl Med; 2013 Feb; 27(2):97-104. PubMed ID: 23420146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
    Barwick T; Bencherif B; Mountz JM; Avril N
    Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
    Couturier O; Leost F; Campone M; Carlier T; Chatal JF; Hustinx R
    Bull Cancer; 2005 Sep; 92(9):789-98. PubMed ID: 16203269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET and PET/CT.
    Krause BJ; Schwarzenböck S; Souvatzoglou M
    Recent Results Cancer Res; 2013; 187():351-69. PubMed ID: 23179888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET and PET-CT. State of the art and future prospects.
    Fanti S; Franchi R; Battista G; Monetti N; Canini R
    Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]FLT-PET in oncology: current status and opportunities.
    Been LB; Suurmeijer AJ; Cobben DC; Jager PL; Hoekstra HJ; Elsinga PH
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1659-72. PubMed ID: 15565331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.